Clinical significance of distal embolism in intravascular recanalization of the superficial femoral artery
https://doi.org/10.15829/1728-8800-2023-3512
EDN: GQSYOB
Abstract
The article discusses different views on distal embolism in endovascular revascularization of lower limb arteries. Attention is drawn to the contribution of the drug coating of the balloon catheter to the development of distal embolization.
About the Authors
O. S. Osipova
Research Department of Vascular and Hybrid Surgery, Institute of Circulatory Pathology, Meshalkin National Medical Research Center
Russian Federation
Russian Federation
Novosibirsk
A. A. Gostev
Research Department of Vascular and Hybrid Surgery, Institute of Circulatory Pathology, Meshalkin National Medical Research Center
Russian Federation
Russian Federation
Novosibirsk
A. A. Karpenko
Research Department of Vascular and Hybrid Surgery, Institute of Circulatory Pathology, Meshalkin National Medical Research Center
Russian Federation
Russian Federation
Novosibirsk
References
1. Katsanos K, Spiliopoulos S, Paraskevopoulos I, et al. Systematic Review and Meta-analysis of Randomized Controlled Trials of Paclitaxel-Coated Balloon Angioplasty in the Femoropopliteal Arteries: Role of Paclitaxel Dose and Bioavailability. J Endovasc Ther. 2016;23(2):356-70. doi:10.1177/1526602815626557.
2. Katsanos K, Spiliopoulos S, Kitrou P, et al. Risk of Death and Amputation with Use of Paclitaxel-Coated Balloons in the Infrapopliteal Arteries for Treatment of Critical Limb Ischemia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. J Vasc Interv Radiol. 2020;31(2):202-12. doi:10.1016/j.jvir.2019.11.015.
3. Ochoa Chaar CI, Shebl F, Sumpio B, et al. Distal embolization during lower extremity endovascular interventions. J Vasc Surg. 2017;66(1):143-50. doi:10.1016/j.jvs.2017.01.032.
4. Mendes BC, Oderich GS, Fleming MD, et al. Clinical significance of embolic events in patients undergoing endovascular femoropopliteal interventions with or without embolic protection devices. J Vasc Surg. 2014;59(2):359-67. doi:10.1016/J.JVS.2013.07.119.
5. Karnabatidis D, Katsanos K, Kagadis GC, et al. Distal embolism during percutaneous revascularization of infra-aortic arterial occlusive disease: an underestimated phenomenon. J Endovasc Ther. 2006;13(3):269-80. doi:10.1583/05-1771.1.
6. Lam RC, Lin SC, DeRubertis B, et al. The impact of increasing age on anatomic factors affecting carotid angioplasty and stenting. J Vasc Surg. 2007;45(5):875-80. doi:10.1016/j.jvs.2006.12.059.
7. Spiliopoulos S, Theodosiadou V, Koukounas V, et al. Distal macro- And microembolization during subintimal recanalization of femoropopliteal chronic total occlusions. J Endovasc Ther. 2014;21(4):474-81. doi:10.1583/14-4703.1.
8. Shrikhande GV, Khan SZ, Hussain HG, et al. Lesion types and device characteristics that predict distal embolization during percutaneous lower extremity interventions. J Vasc Surg. 2011;53(2):347-52. doi:10.1016/J.JVS.2010.09.008.
9. Lam RC, Shah S, Faries PL, et al. Incidence and clinical significance of distal embolization during percutaneous interventions involving the superficial femoral artery. J Vasc Surg. 2007; 46(6):1155-9. doi:10.1016/j.jvs.2007.07.058.
10. Brancaccio G, Lombardi R, Stefanini T, et al. Comparison of embolic load in femoropopliteal interventions: percutaneous transluminal angioplasty versus stenting. Vasc Endovascular Surg. 2012;46(3):229-35. doi:10.1177/1538574411422276.
11. Zeller T, Schmidt A, Rastan A, et al. New approach to protected percutaneous transluminal angioplasty in the lower limbs. J Endovasc Ther. 2013;20(3):409-19. doi:10.1583/13-4221.1.
12. Almeida SO, Budoff M. Effect of statins on atherosclerotic plaque. Trends Cardiovasc Med. 2019;29(8):451-5. doi:10.1016/j.tcm.2019.01.001.
13. Tepe G, Schnorr B, Albrecht T, et al. Angioplasty of femoral-popliteal arteries with drug-coated balloons: 5-year follow-up of the THUNDER trial. JACC Cardiovasc Interv. 2015;8(1 Pt A):102-8. doi:10.1016/J.JCIN.2014.07.023.
14. Brodmann M, Werner M, Meyer DR, et al. Sustainable Antirestenosis Effect With a Low-Dose Drug-Coated Balloon: The ILLUMENATE European Randomized Clinical Trial 2-Year Results. JACC Cardiovasc Interv. 2018;11(23):2357-64. doi:10.1016/J.JCIN.2018.08.034.
15. Schneider PA, Laird JR, Tepe G, et al. Treatment Effect of Drug-Coated Balloons Is Durable to 3 Years in the Femoropopliteal Arteries: Long-Term Results of the IN.PACT SFA Randomized Trial. Circ Cardiovasc Interv. 2018;11(1):e005891. doi:10.1161/CIRCINTERVENTIONS.117.005891.
16. Jaff MR, Nelson T, Ferko N, et al. Endovascular Interventions for Femoropopliteal Peripheral Artery Disease: A Network Meta-Analysis of Current Technologies. J Vasc Interv Radiol. 2017;28(12):1617-27.e1. doi:10.1016/J.JVIR.2017.08.003.
17. Teichgräber UK, Klumb C. Drug-coated Balloon Angioplasty in Femoropopliteal Arteries — Is There a Class Effect? Zentralbl Chir. 2017;142(5):470-80. doi:10.1055/S-0043-119895.
18. Ibragimov TR, Galimov OV, Khanov VO, et al. The use of balloon drug-coated catheters in patients with diabetic foot syndrome. Bulletin of the Russian Scientific Center for Roentgen Radiology of the Ministry of Health of Russia. 2018;18(1):6. (In Russ.)
19. Zatevakhin II, Shipovsky VN, Dzhurakulov ShR. Long-term results of angioplasty using drug-coated balloons in lesions of the femoropopliteal segment. International Journal of Interventional Cardioangiology. 2013;20(4):64-8. (In Russ.)
20. Sharafutdinov MR, Yakubov RA, Tarasov YuV, et al. Comparison of directed tube atherectomy and drug coated balloons in patients with femoral artery lesions. Practical Medicine. 2017;(4):11-4. (In Russ.)
21. Aboyans V, Ricco JB, Bartelink MLEL, et al. Editor’s Choice — 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS). Eur J Vasc Endovasc Surg. 2018;55(3):305-68. doi:10.1016/j.ejvs.2017.07.018.
22. Katsanos K, Spiliopoulos S, Teichgräber U, et al. Editor’s Choice — Risk of Major Amputation Following Application of Paclitaxel Coated Balloons in the Lower Limb Arteries: A Systematic Review and Meta-Analysis of Randomised Controlled Trials. Eur J Vasc Endovasc Surg. 2022;63(1):60-71. doi:10.1016/j.ejvs.2021.05.027.
23. Conte MS, Bradbury AW, Kolh P, et al. Global vascular guidelines on the management of chronic limb-threatening ischemia. J Vasc Surg. 2019;58(1):1-109. doi:10.1016/J.JVS.2019.02.016.
24. Kelsch B, Scheller B, Biedermann M, et al. Dose response to Paclitaxel-coated balloon catheters in the porcine coronary overstretch and stent implantation model. Invest Radiol. 2011;46(4):255-63. doi:10.1097/RLI.0B013E31820577DF.
25. Speck U, Cremers B, Kelsch B, et al. Do pharmacokinetics explain persistent restenosis inhibition by a single dose of paclitaxel? Circ Cardiovasc Interv. 2012;5(3):392-400. doi:10.1161/CIRCINTERVENTIONS.111.967794.
26. Stolzenburg N, Breinl J, Bienek S, et al. Paclitaxel-Coated Balloons: Investigation of Drug Transfer in Healthy and Atherosclerotic Arteries — First Experimental Results in Rabbits at Low Inflation Pressure. Cardiovasc Drugs Ther. 2016;30(3):263-70. doi:10.1007/S10557-016-6658-1.
27. Torii S, Jinnouchi H, Sakamoto A, et al. Comparison of Biologic Effect and Particulate Embolization after Femoral Artery Treatment with Three Drug-Coated Balloons in Healthy Swine Model. J Vasc Interv Radiol. 2019;30(1):103-9. doi:10.1016/J.JVIR.2018.07.025.
28. Kolodgie FD, Pacheco E, Yahagi K, et al. Comparison of Particulate Embolization after Femoral Artery Treatment with IN.PACT Admiral versus Lutonix 035 Paclitaxel-Coated Balloons in Healthy Swine. J Vasc Interv Radiol. 2016;27(11):1676-85.e2. doi:10.1016/J.JVIR.2016.06.036.
29. Lake E, Twigg M, Farquharson F. Acute hypersensitivity reaction to femoral drug-coated balloons. Vasa. 2017;46(3):223-5. doi:10.1024/0301-1526/A000604.
30. Thomas SD, McDonald RRA, Varcoe RL. Vasculitis resulting from a superficial femoral artery angioplasty with a paclitaxel-eluting balloon. J Vasc Surg. 2014;59(2):520-3. doi:10.1016/J.JVS.2013.03.013.
31. Cai H, Dong J, Ye Y, et al. Safety and Efficacy of Drug-Coated Balloon in the Treatment of Below-the-Knee Artery: A Meta-analysis. J Surg Res. 2022;278:303-16. doi:10.1016/J.JSS.2022.04.055.
32. Stettler C, Wandel S, Allemann S, et al. Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet. 2007;370(9591):937-48. doi:10.1016/S0140-6736(07)61444-5.
33. Perez EA, Suman VJ, Davidson NE, et al. Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial. J Clin Oncol. 2008;26(8):1231-8. doi:10.1200/JCO.2007.13.5467.
34. Hayes DF, Thor AD, Dressler LG, et al. HER2 and response to paclitaxel in node-positive breast cancer. N Engl J Med. 2007;357(15):1496-506. doi:10.1056/NEJMOA071167.
35. Dake MD, Ansel GM, Jaff MR, et al. Correction to: Durable Clinical Effectiveness with Paclitaxel-Eluting Stents in the Femoropopliteal Artery 5-Year Results of the Zilver PTX Randomized Trial. Circulation. 2019;139(8):E42. doi:10.1161/CIR.0000000000000657.
36. Schneider PA, Laird JR, Doros G, et al. Mortality Not Correlated with Paclitaxel Exposure: An Independent Patient-Level Meta-Analysis of a Drug-Coated Balloon. J Am Coll Cardiol. 2019;73(20):2550-63. doi:10.1016/J.JACC.2019.01.013.
37. Papoyan SA, Shchegolev AA, Gromov DG, et al. Drug-coated balloon angioplasty in peripheral arterial disease. Russian Medical Inquiry. 2022;6(4):177-81. doi:10.32364/2587-6821-2022-6-4-177-181.
Supplementary files
What is already known about the subject?
- In connection with the identification of an increased risk of large lower extremity amputations after angioplasty of lower extremity arteries using drug-eluting balloons according to meta-analyses and the presence of distal embolism in endovascular recanalization, studies are being conducted to investigate the possibility of an embolism with a cytostatic coating and its clinical role.
What might this study add?
- Preclinical studies have demonstrated embolism after arterial angioplasty with drug-coated balloons.
- There are no clinical studies demonstrating distal embolization with drug coating particles and describing their short-term and long-term clinical effects.
Review
For citations:
Osipova O.S., Gostev A.A., Karpenko A.A. Clinical significance of distal embolism in intravascular recanalization of the superficial femoral artery. Cardiovascular Therapy and Prevention. 2023;22(6):3512. (In Russ.) https://doi.org/10.15829/1728-8800-2023-3512. EDN: GQSYOB
Views:
816
Email this article 
